文献速递头颈部肿瘤放疗

局部RGTA未能降低头颈癌放化疗联合西妥昔单抗所致放射性皮炎:多中心随机双盲安慰剂对照GORTEC 2009-01试验

Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-07-22

该多中心随机双盲安慰剂对照试验评估局部再生剂OTD70DERM(RGTA)对头颈癌患者接受常规分割放疗(70 Gy/35次)联合同期西妥昔单抗所致放射性皮炎的影响。共随机76例,最终72例可评估放射性皮炎。

要点

  • 局部RGTA未降低头颈癌放化疗联合西妥昔单抗患者≥2级放射性皮炎的发生率。
  • 两组≥2级放射性皮炎发生率分别为81%与80%,差异无统计学意义。
  • RGTA对皮肤生活质量指数评分亦无显著改善。

核心结论

  • 尽管临床前研究显示RGTA可减少放射性黏膜和皮肤毒性,但本试验中局部RGTA未能降低头颈癌患者放射性皮炎的发生率和严重程度。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验纳入新诊断头颈癌患者,接受常规分割放疗(70 Gy/35次)联合每周西妥昔单抗,按1:1随机接受局部OTD70DERM或安慰剂每日一次。
  • 共随机76例(每组38例),72例可进行最终放射性皮炎评估(RGTA组37例,安慰剂组35例)。
  • 采用NCI CTCAE v3.0基于照射区照片评估放射性皮炎,并由2名外部专家独立评分,同时评估皮肤病生活质量指数。

临床怎么用

  • 对于接受放疗联合西妥昔单抗的头颈癌患者,不应基于本试验结果常规使用局部RGTA预防放射性皮炎。

局限性

  • 最终放射性皮炎评估仅72例可评估,样本量较小。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Concomitant cetuximab and radiation therapy (RT) can induce severe radiodermatitis in patients with head and neck cancer (HNC). OTD70DERM, a regenerating agent (RGTA), is a structural and functional analogue of glycosaminoglycans. Preclinical studies have shown that topical RGTA can markedly reduce radiation-induced mucosal and cutaneous toxicities without tumor protection. The present study aimed to evaluate the effect of topical RGTA on radiodermatitis in patients with HNC undergoing RT and cetuximab, for whom RT-induced skin reactions are frequent and/or severe. The primary endpoint was the incidence of grade ≥2 radiodermatitis. METHODS AND MATERIALS: We performed a multicenter, randomized, double-blind, placebo-controlled trial of patients with newly diagnosed HNC undergoing conventionally fractionated RT (70 Gy in 35 fractions) and weekly cetuximab. Patients were randomized 1:1 to receive topical OTD70DERM or placebo on irradiated skin once daily. The National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, was used to evaluate radiodermatitis (photographs of radiation zone). The Dermatology Life Quality Index score was also evaluated. All the skin reactions seen on the photographs were scored independently by 2 outside experts. RESULTS: Of the 76 randomized patients (38 in each arm), 72 were available for the final radiodermatitis evaluation (37 in the RGTA arm and 35 in the placebo arm). No significant difference was observed concerning the incidence or duration of grade ≥2 radiodermatitis between the 2 arms (81% for RGTA vs 80% for placebo; P=.9). Also, no significant difference was found between the 2 arms regarding grade ≥2 radiodermatitis evaluated by the 2 experts using the photographs of 68 patients (76% vs 74%; P=.78). Finally, no significant difference was found in the Dermatology Life Quality Index score (score >10, 15% vs 20%; P=.45). CONCLUSIONS: Despite the good preclinical rationale, RGTA did not reduce the incidence and severity of radiodermatitis in patients with HNC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tao Y, Auperin A, Sire C, et al. Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280453. doi:10.1016/j.ijrobp.2017.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。